Results 251 to 260 of about 21,053 (285)

Cerebral venous sinus thrombosis with cold agglutinin disease in summer: illustrative case. [PDF]

J Neurosurg Case Lessons
Kobayashi Y, Nishimura S, Takemura A, Okuyama S, Takahashi A, Kubota K, Matsuyama J, Matsushima T, Takahashi M.   +8 more
europepmc   +1 more source

Association Between Statins Use and Major Bleeding in Patients Using Direct Oral Anticoagulants for Atrial Fibrillation. [PDF]

Pharmacoepidemiol Drug Saf
de Burgos-González A, Cea-Soriano L, Huerta-Álvarez C.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Lancet, The, 2019
Pascal Vranckx, Marco Valgimigli, Thorsten Lewalter   +2 more
exaly   +2 more sources

Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial

Circulation, 2023
BACKGROUND: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking.
Y. Yamashita, T. Morimoto, N. Muraoka, T. Oyakawa, M. Umetsu, D. Akamatsu, Y. Nishimoto, Yukihito Sato, T. Takada, K. Jujo, Y. Minami, Y. Ogihara, K. Dohi, Masashi Fujita, T. Nishikawa, N. Ikeda, G. Hashimoto, K. Otsui, Kenta Mori, D. Sueta, Y. Tsubata, M. Shoji, A. Shikama, Y. Hosoi, Y. Tanabe, R. Chatani, Kengo Tsukahara, N. Nakanishi, Kitae Kim, S. Ikeda, M. Mo, Yusuke Yoshikawa, Takeshi Kimura   +32 more
semanticscholar   +1 more source

Edoxaban

Reactions Weekly
  +12 more sources

Edoxaban Tosylate

American Journal Cardiovascular Drugs, 2011
Daiichi Sankyo is developing edoxaban tosylate (DU 176b; DU-176; DU-176b; DU176b) as an orally active direct factor Xa inhibitor for the prevention of stroke and the prevention and treatment of venous thromboembolism. Two dosing regimens of edoxaban tosylate are being compared with warfarin over 24 months in the ENGAGE AF TIMI 48 trial (NCT00781391) in
openaire   +2 more sources

Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.

New England Journal of Medicine
BACKGROUND Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary artery disease are still lacking.
Min-Soo Cho, Do-Yoon Kang, Jung‐Min Ahn, S. Yun, Y. Oh, Chang Hoon Lee, Eue-Keun Choi, Ji Hyun Lee, Chang Hee Kwon, Gyung-Min Park, Hyung Oh Choi, Kyoung-Ha Park, Kyoung-Min Park, Jongmin Hwang, Ki-Dong Yoo, Y. Cho, Ji Hyun Kim, K. W. Hwang, Eun-Sun Jin, O. Kwon, Ki-Hun Kim, Seung-Jung Park, D. Park, Gi-Byoung Nam   +23 more
semanticscholar   +1 more source

Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.

JAMA cardiology
Importance In older patients with atrial fibrillation who take anticoagulants for stroke prevention, bleeding is increased compared with younger patients, thus, clinicians frequently prescribe lower than recommended doses in older patients despite ...
Andre Zimerman, E. Braunwald, J. Steffel, N. V. Van Mieghem, M. Palazzolo, S. Murphy, Cathy Chen, M. Unverdorben, C. Ruff, E. Antman, R. Giugliano   +10 more
semanticscholar   +1 more source

Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosis.

Cardiology in the Young, 2023
BACKGROUND Direct oral anticoagulants have the potential to improve care in children requiring chronic anticoagulation. Edoxaban has favourable pharmacokinetics that could benefit younger patients but data on long-term safety and efficacy for specific ...
E. Sagiv, D. Newland, April E Slee, A. Olson, M. Portman   +4 more
semanticscholar   +1 more source